Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Giacomo Barchiesi, Amelia McCartney, Chiara Biagioni, Olimpia Siclari, Lorenzo Rossi, Marta Pestrin, Angelo Di Leo, Laura Biganzoli

Research output: Contribution to journalArticle

Abstract

Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS, and DRFI were 77% and 65%; 60% and 46%; and 74% and 73%, respectively. Forty-seven patients did not receive chemotherapy. A separate analysis was performed excluding those patients. In this subgroup, 5- and 10-year OS, DFS, and DRFI were 86% and 77%; 68% and 54%, 77% both at 5 and 10 years. Prognosis is better than previously described; adjuvant chemotherapy should be offered to fit elderly patients if clinically warranted.

Original languageEnglish
Pages (from-to)1225-1229
Number of pages5
JournalBreast Journal
Volume25
Issue number6
DOIs
Publication statusPublished - Nov 1 2019
Externally publishedYes

Keywords

  • breast cancer
  • elderly
  • outcome
  • prognosis
  • triple negative

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution'. Together they form a unique fingerprint.

Cite this